TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01584557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan or Samsca
Description: uncoated tablet, 30mg, once per day, for up to 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo or sugar pill
Description: sugar pill
Study: NCT03159702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
Study: NCT00681590

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vitamin D)
Description: 400 IU daily (low dose)
Study: NCT02951455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.
Study: NCT00681590

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vitamin D)
Description: 2000 IU daily (high dose)
Study: NCT03915353

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT02116608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Apply locally as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Butyrate Cream, 1.0%
Description: Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
Study: NCT03043976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph GT9X Link device
Description: Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph GT9X Link device
Description: Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Actigraph GT9X Link device
Description: Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased
Study: NCT00922272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (lisdexamfetamine dimesylate)
Description: oral, 20, 30, 40, 50, 60, or 70 mg once daily
Study: NCT02951455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.
Study: NCT01197781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSTAMATIN
Description: Oral tablets - single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSTAMATIN
Description: Oral tablets - single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Oral tablets - administered 3 times daily over 4 days
Study: NCT02708966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gymnema Sylvestre
Description: Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
Study: NCT03739736

Intervention type: OTHER
Intervention: Combination of TB/HIV prevention activities (arm A)
Description: The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)

Intervention type: OTHER
Intervention: Combination of TB/HIV prevention activities (arm B)
Description: The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)

Intervention type: OTHER
Intervention: Standard of care (arm C)
Description: The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm.
Study: NCT04456608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
Study: NCT05045248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraclonidine Hcl 0.5% Oph Soln
Description: Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
Study: NCT04266249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Description: Undergo mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Description: Undergo mastectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study: NCT03159702

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200 cGy on Day: -1
Study: NCT03076008

Intervention type: OTHER
Intervention: Observational
Description: No intervention
Study: NCT04343521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted Indoor Residual Spraying (TIRS)
Description: Spraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán.
Study: NCT03841617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyrogen
Description: intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-131
Description: therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-131
Description: therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-124
Description: one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-124
Description: one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid hormone withdrawal
Description: withdrawal of thyroid hormone during weeks 4 through 8
Study: NCT04799704

Intervention type: DIAGNOSTIC_TEST
Intervention: swabbing of conjunctiva
Description: Each eye will be sampled with a single, sterile, nylon, flocked swab
Study: NCT01154582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg snack
Description: subject consume 4 cooked whole eggs, providing 380 kcal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cottage cheese
Description: Subjects consume 200 g of cottage cheese, providing 380 kcal
Study: NCT04551755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin and Doxycycline
Description: 1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
Study: NCT02359760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Flapless corticotomies
Study: NCT03713359

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trial arm (MRVAC)
Description: Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
Study: NCT03804697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selective anticoagulation
Description: Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selective anticoagulation
Description: Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
Study: NCT03755297

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample analysis of patients treated as standard care
Description: Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample analysis of patients treated as standard care
Description: Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample analysis of patients treated as standard care
Description: Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
Study: NCT02781597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 0.9% normal saline
Study: NCT01023932

Intervention type: DEVICE
Intervention: Cochlear Implants
Study: NCT03179930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
Study: NCT03384095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Description: Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
Study: NCT03179930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg IV on D1
Study: NCT00564772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir, lopinavir, ritonavir
Description: 4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
Study: NCT03184831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus lift, implant placement, sole bovine bone
Description: sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift, implant placement, injectable PRF + bovine bone
Description: sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
Study: NCT01727297

Intervention type: DEVICE
Group type: OTHER
Intervention: REVEAL Implantable Cardiac Monitor
Study: NCT04546230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Thoracic Epidural Anesthesia
Description: Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
Study: NCT02846311

Intervention type: DEVICE
Intervention: Flu Test
Study: NCT04437511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Given IV
Study: NCT01991691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-based questionnaire
Description: tablet-based patient reported outcomes (TabPRO)
Study: NCT02295488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological sampling
Description: blood intake for biological sampling during validated desensitization protocol (Alyostall®)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desensitization protocol (Alyostall®)
Description: Validated desensitization protocol using Alyostall® performed
Study: NCT04437511

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study: NCT04266249

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study: NCT04332562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary restriction (salt restriction)
Description: salt restriction for one week after being diagnosed with hypertension
Study: NCT01830478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
Study: NCT03882723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluated 4 masks used for NIV with mechanical ventilators
Description: Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
Study: NCT03039790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.
Study: NCT01830478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
Study: NCT03060538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Administered subcutaneously starting on Day 1 and according to dosing schedule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously starting on Day 1 and according to dosing schedule.
Study: NCT00814164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative Study